Author:
Escudero-Ortiz Vanesa,Pérez-Ruixo Juan José,Valenzuela Belén
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Pharmacology (medical),Pharmacology
Reference21 articles.
1. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.;Nelson;Ann Pharmacother,2006
2. . The effects of the novel, reversible epidermal growth factor receptorErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.;Rusnak;Mol Cancer Ther,2001
3. . Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.;Scheffler;Clin Pharmacokinet,2011
4. . Effects of food on the relative bioavailability of lapatinib in cancer patients.;Koch;J Clin Oncol,2009
5. . Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.;Nakagawa;Jpn J Clin Oncol,2009
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献